International Stroke Conference 2025  /  Imaging Posters II  /  Hidden Core: Unveiling the Clinical Impact of CTP-Invisible Ischemic Lesions in Large Vessel Occlusion Stroke Treated with Thrombectomy
Logo

American Heart Association

  11
  0

Final ID: TP175

Hidden Core: Unveiling the Clinical Impact of CTP-Invisible Ischemic Lesions in Large Vessel Occlusion Stroke Treated with Thrombectomy

Abstract Body: Background and Purpose:
Acute ischemic stroke (AIS) may present with an estimated core of 0 ml on CT perfusion imaging without a visible decrease in cerebral blood flow (CBF) maps. When the ischemic core is not visible, assessing the full extent of stroke severity can be challenging. We assessed the clinical outcomes of patients with and without a CBF core at stroke onset, who underwent mechanical thrombectomy.
Methods:
Data from the National Cerebral and Cardiovascular Center Endovascular Thrombectomy database (January 2018 to April 2024) were analyzed. Anterior circulation AIS patients with large vessel occlusion were grouped based on the presence of a CBF core, defined as either 0 mL or greater than 0 mL, with a relative CBF less than 30% of normally perfused tissue on CT perfusion imaging. The primary outcome was a modified Rankin Scale (mRS) score of 0-2 at 90 days. Secondary outcomes included mRS 0-1 at 90 days, symptomatic intracranial hemorrhage (sICH), and death.
Results:
A total of 704 patients (mean age 75±13 years, 52% women) were included in the study, with 214 having no CBF core (0 mL) and 490 having a CBF core. Median CBF core volume in the CBF core group was 26 mL (IQR 12-64). The median baseline NIHSS score was significantly lower in the no CBF core group (13; IQR 7-18) compared to the CBF core group (19; IQR 14-25, p < 0.01). Additionally, the no CBF core group had higher hemoglobin levels (p <0.01) and a lower percentage of M1distal (M1d) occlusion (15% vs. 23%, p=0.02). The rate of intravenous thrombolysis (45% vs. 39%, p=0.13) and the median time from onset to imaging (143 minutes vs. 162 minutes, p=0.43) were similar between groups. Favorable outcomes (mRS 0-2 at 90 days) were significantly more frequent in the no CBF core group (44% vs. 34%, p=0.01), as were excellent outcomes (32% vs. 20%, p <0.01). There was no significant difference in rates of sICH (4% vs. 3% p=0.81) and death (5% vs. 8%, p=0.26) between the groups. Logistic regression analysis, adjusted for age, sex, NIHSS, hemoglobin, blood glucose, M1d occlusion, and intravenous thrombolysis, showed a significant association between the absence of a CBF core and favorable outcomes, with an adjusted OR of 1.51 (95% CI 1.00-2.25, p=0.04).
Conclusions:
Stroke patients without a CBF core at baseline have better clinical outcomes. The higher incidence of M1d occlusions in the CBF core group suggests that these patients have poorer collateral flow, leading to more evident decreases in CBF.
  • Inoue, Manabu  ( NATL CEREBRAL CARDIOVASCULAR CTR , Osaka , Japan )
  • Ihara, Masafumi  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Koga, Masatoshi  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Albers, Greg  ( Stanford University , Stanford , California , United States )
  • Toyoda, Kazunori  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Kamogawa, Naruhiko  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Yoshie, Tomohide  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Abe, Soichiro  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Ishiyama, Hiroyuki  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Shiozawa, Masayuki  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Yamaguchi, Eriko  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Imamura, Hirotoshi  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
  • Kataoka, Hiroharu  ( Natl Cerebral and Cardiovascular Ct , Suita , Japan )
    • Author Disclosures:
    Manabu Inoue: DO NOT have relevant financial relationships | Masafumi Ihara: DO NOT have relevant financial relationships | Masatoshi Koga: DO have relevant financial relationships ; Research Funding (PI or named investigator):Nippon Boehringer Ingelheim:Past (completed) ; Research Funding (PI or named investigator):Daiichi-Sankyo:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Expected (by end of conference) ; Speaker:Otsuka Pharmaceutical:Past (completed) ; Speaker:BMS/Pfizer:Past (completed) ; Speaker:Mitsubishi Tanabe Pharma Corporation:Past (completed) ; Speaker:Bayer Yakuhin:Past (completed) ; Speaker:AstraZeneca:Past (completed) ; Speaker:Daiichi-Sankyo:Active (exists now) ; Advisor:BMS/Janssen Pharmaceuticals:Active (exists now) | Greg Albers: DO have relevant financial relationships ; Consultant:iSchemaView:Active (exists now) ; Consultant:Genentech:Past (completed) ; Ownership Interest:iSchemaView:Active (exists now) | Kazunori Toyoda: DO have relevant financial relationships ; Speaker:BMS:Active (exists now) ; Speaker:Bayer:Active (exists now) ; Speaker:Daiichi-Sankyo:Active (exists now) ; Speaker:Otsuka:Active (exists now) ; Advisor:Janssen:Active (exists now) | Naruhiko Kamogawa: DO NOT have relevant financial relationships | Tomohide Yoshie: DO NOT have relevant financial relationships | Soichiro Abe: DO NOT have relevant financial relationships | Hiroyuki Ishiyama: DO NOT have relevant financial relationships | Masayuki Shiozawa: DO NOT have relevant financial relationships | Eriko Yamaguchi: No Answer | Hirotoshi Imamura: No Answer | Hiroharu Kataoka: DO NOT have relevant financial relationships
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Imaging Posters II

Thursday, 02/06/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
Association of pre-thrombectomy infarct topography and hemorrhagic transformation in patients with acute ischemic stroke: A multicenter Bayesian analysis

Bonkhoff Anna, Simonsen Claus, Patel Aman, Rost Natalia, Regenhardt Robert, Schirmer Markus, Favilla Christopher, Das Alvin, Dmytriw Adam, Gupta Rajiv, Rabinov James, Stapleton Christopher, Leslie-mazwi Thabele

A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke

Xu Xiaohong, Preeti Preeti, Yu Ruoying, Shaykhalishahi Hamed, Zhang Cheng, Shen Chuanbin, Li Bei, Tang Naping, Chang Yan, Xiang Qian, Cui Yimin, Lei Xi, Ni Heyu, Zhu Guangheng, Liu Zhenze, Hu Xudong, Slavkovic Sladjana, Neves Miguel, Ma Wenjing, Xie Huifang

More abstracts from these authors:
Pathological and Clinical Findings of Calcified Nodules in Carotid Artery Stenosis

Yamada Kiyofumi, Hatakeyama Kinta, Amemiya Kisaki, Abe Soichiro, Shirakawa Manabu, Imamura Hirotoshi, Iihara Koji, Yoshimura Shinichi, Kataoka Hiroharu

Evaluating Exemption from Informed Consent and Deferred Consent Practices in Acute Stroke Trials:
A Scoping Review of Recent Trends and Recruitment Efficiency．

Fukuda-doi Mayumi, Koga Masatoshi, Inoue Manabu, Yoshimura Sohei, Ishigami Akiko, Yamaguchi Eriko, Yamamoto Haruko, Toyoda Kazunori

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)